What is "miglustat"

n. A drug used primarily to treat certain kinds of Gaucher's disease by inhibiting glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids.

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I Gaucher disease (GD1). It is marketed under the trade name Zavesca.